FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Vashington,	D.C.	20549	
vasimigton,	D.O.	20040	

vvasimigton,	D.C. 20040	

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response	e: 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Barbarosh Craig A.					LIF	2. Issuer Name and Ticker or Trading Symbol LIFECORE BIOMEDICAL, INC. \DE\ [LFCR]								(Ch	eck all app X Direc	licable) tor	ng Pei	rson(s) to Iss	/ner	
(Last)	,	rst) ((Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/31/2023										belov	er (give title v)		Other (s below)	pecify
3515 LYMAN BLVD						4. If Amendment, Date of Original Filed (Month/Day/Year)								Lin	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street)	A M	N !	55318														filed by Mo		n One Repo	
(City)	(Si	tate) ((Zip)		_	Rule 10b5-1(c) Transaction Indication														
Check this box to indicate the satisfy the affirmative defense									e tnat a tr fense con	ansa ditior	ction was is of Rule	made 10b5-1	.(c). Se	e Instruc	ntract, instrution 10.	ction or writte	en pian	that is intend	led to	
		Table	e I - Non	-Deriva	ative \$	Sec	uriti	es Ac	qui	ired, C	isp	osed	of, oı	Ben	eficia	lly Own	ed			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				Execution Date		Code (Instr.		4. Securities Acquired (Disposed Of (D) (Instr. 3			Benefi	ies For cially (D) Following (I) (n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
										Code	V	Amoun	t	(A) or (D)	Price	Transa	action(s) 3 and 4)		"	,iii3u. 4)
Common Stock 05/3				05/31/	/2023					M		9,47	'4	A	(1)(2	3	0,337		I	In Trust
		Tá	able II - [)	Derivat e.g., pu												y Owne	i			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	Code (Instr		n of		6. Date Exercisable at Expiration Date (Month/Day/Year)			e and 7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Dat Exe	te ercisable		piration tte	Title	0 N	Amount or Number of Shares					
Restricted Stock	(1)	05/31/2023			M			9,474		(2)		(2)	Comr		9,474	\$0	0		I	In Trust

Explanation of Responses:

- 1. The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
- 2. The restricted stock units vested on May 31, 2023.

Remarks:

/s/ Aaron Perlitsh, Attorney-In-06/01/2023 Fact for Craig Barbarosh

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.